Aberdeen Group plc Purchases Shares of 625,000 Aquestive Therapeutics, Inc. $AQST

Aberdeen Group plc acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 625,000 shares of the company’s stock, valued at approximately $3,494,000.

Other large investors have also made changes to their positions in the company. Commonwealth Equity Services LLC acquired a new position in Aquestive Therapeutics in the third quarter valued at $5,918,000. Federated Hermes Inc. purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter worth about $4,381,000. Sio Capital Management LLC lifted its stake in shares of Aquestive Therapeutics by 141.9% in the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after purchasing an additional 555,860 shares in the last quarter. Everstar Asset Management LLC grew its holdings in shares of Aquestive Therapeutics by 119.5% during the 2nd quarter. Everstar Asset Management LLC now owns 658,607 shares of the company’s stock worth $2,180,000 after purchasing an additional 358,607 shares during the period. Finally, Pale Fire Capital SE grew its holdings in shares of Aquestive Therapeutics by 25.5% during the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after purchasing an additional 340,767 shares during the period. 32.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AQST shares. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Piper Sandler increased their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $8.50.

Aquestive Therapeutics Price Performance

NASDAQ:AQST opened at $3.95 on Friday. The firm has a 50-day moving average of $4.56 and a two-hundred day moving average of $5.18. The stock has a market cap of $481.90 million, a P/E ratio of -5.56 and a beta of 1.65. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $7.55.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.